BioPharma Resources

Drug Trial Radar · NCT07776509

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Aug 9, 2028

Study completion Aug 9, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.

Conditions

  • Obesity or Overweight
  • Weight-Related Comorbidity
  • With/Without Diabetes Mellitus, Type 2

Interventions

  • LenbelintideDrug

    IMP injected subcutaneously, once a week.

  • PlaceboDrug

    Placebo matching IMP dose injected subcutaneously, once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from baseline at 68 weeks of treatmentTime frame: 68 weeks

Locations

96 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Escondido, California · Not yet recruiting

  • Research Site

    Lincoln, California · Recruiting

  • Research Site

    Walnut Creek, California · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Stockbridge, Georgia · Recruiting

  • Research Site

    Woodstock, Georgia · Recruiting

  • Research Site

    Champaign, Illinois · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Beltsville, Maryland · Not yet recruiting

  • Research Site

    Oxon Hill, Maryland · Not yet recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    Las Vegas, Nevada · Not yet recruiting

  • Research Site

    Somerset, New Jersey · Not yet recruiting

  • Research Site

    Statesville, North Carolina · Recruiting

  • Research Site

    Fargo, North Dakota · Recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Smithfield, Pennsylvania · Recruiting

  • Research Site

    Franklin, Tennessee · Not yet recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Manassas, Virginia · Not yet recruiting

  • Research Site

    Renton, Washington · Withdrawn

  • Research Site

    Buenos Aires, Argentina · Recruiting

  • Research Site

    CABA, Argentina · Recruiting

  • Research Site

    Ciudad de Buenos Aires, Argentina · Recruiting

  • Research Site

    Ramos Mejía, Argentina · Not yet recruiting

  • Research Site

    Rosario, Argentina · Recruiting

  • Research Site

    San Nicolás, Argentina · Not yet recruiting

  • Research Site

    Belo Horizonte, Brazil · Not yet recruiting

  • Research Site

    Campinas, Brazil · Recruiting

  • Research Site

    Campinas, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Calgary, Alberta, Canada · Recruiting

  • Research Site

    Calgary, Alberta, Canada · Recruiting

  • Research Site

    Surrey, British Columbia, Canada · Recruiting

  • Research Site

    Vancouver, British Columbia, Canada · Recruiting

  • Research Site

    Guelph, Ontario, Canada · Recruiting

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.